|Source:||The tubers of Corydalis decumbens (Thunb.) Pers.|
|Biological Activity or Inhibitors:||1. Dihydroberberine has anti-tumor activity.
2. Dihydroberberine improves in vivo efficacy in terms of counteracting increased adiposity, tissue triglyceride accumulation, and insulin resistance in high-fat-fed rodents, thus is potential therapeutic reagents for type 2 diabetes treatment.
|Solvent:||Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: email@example.com
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||2.9642 mL||14.821 mL||29.6419 mL||59.2839 mL||74.1048 mL|
|5 mM||0.5928 mL||2.9642 mL||5.9284 mL||11.8568 mL||14.821 mL|
|10 mM||0.2964 mL||1.4821 mL||2.9642 mL||5.9284 mL||7.4105 mL|
|50 mM||0.0593 mL||0.2964 mL||0.5928 mL||1.1857 mL||1.4821 mL|
|100 mM||0.0296 mL||0.1482 mL||0.2964 mL||0.5928 mL||0.741 mL|
Diabetes. 2008 May;57(5):1414-8.
|Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action.[Pubmed: 18285556]|
|The effect of a BBR derivative, Dihydroberberine (dhBBR), on adiposity and glucose metabolism was examined in rodents fed a high-fat diet.A novel BBR derivative, Dihydroberberine, was identified that displayed improved in vivo efficacy in terms of counteracting increased adiposity, tissue triglyceride accumulation, and insulin resistance in high-fat-fed rodents.|
Arch Pharm Res. 1997 Oct;20(5):476-9.
|Studies on the synthesis andin vitro anti-tumor activity of dihydroberberine derivatives.[Pubmed: 18982493]|
|Three types of Dihydroberberine derivatives such as spirobenzylisoquinoline, benzindenoazepine and cyclopropanated quinolizine species were synthesized from Dihydroberberine for the investigation on their anti-tumor activity. Among them, cyclopropanated quinolizine species were more effective than spirobenzylisoquinoline and benzindenoazepine against P-388 and L-1210 leukemia cell.|
Bioorg Med Chem. 2010 Aug 15;18(16):5915-24.
|8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models.[Pubmed: 20663675]|
|The clinical use of the natural alkaloid berberine (BBR) as an antidiabetic reagent is limited by its poor bioavailability. Our previous work demonstrated that Dihydroberberine (dhBBR) has enhanced bioavailability and in vivo efficacy compared with berberine. Here we synthesized the 8,8-dimethylDihydroberberine (Di-Me) with improved stability, and bioavailability over Dihydroberberine. Similar to BBR and Dihydroberberine, Di-Me inhibited mitochondria respiration, increased AMP:ATP ratio, activated AMPK and stimulated glucose uptake in L6 myotubes. Administered to db/db mice with a dosage of 50mg/kg, Di-Me effectively reduced random fed and fasting blood glucose, improved glucose tolerance, alleviated insulin resistance and reduced plasma triglycerides, with better efficacy than Dihydroberberineat the same dosage. Our work highlights the importance of Dihydroberberine analogs as potential therapeutic reagents for type 2 diabetes treatment.|